

## Curriculum Vitae Prof. Dr. Stefan A. Laufer: 24.10.2024



**Address:** Eberhard-Karls-University Tuebingen  
Institute of Pharmacy, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany  
07071-2978788, Mobile: 01749373041, stefan.laufer@uni-tuebingen.de  
<http://www.medchem.uni-tuebingen.de>

**Present position:** Chairman for Pharmaceutical Chemistry,  
Head Medicinal Chemistry Department Pharmacy & Biochemistry  
Director Institute of Pharmacy  
Eberhard-Karls-University Tuebingen, Germany

### **Education:**

1984: Degree in Pharmacy, University of Regensburg  
1989: PhD in Pharmaceutical Chemistry, University of Regensburg  
1997: Habilitation for Pharmaceutical Chemistry, University of Mainz

### **Professional appointments:**

1988-90: Postdoc, Institute of Pharmaceutical Chemistry and Biopharmacy, Frankfurt  
1990-96: Head Department Drug Research,  
Merckle Pharmaceuticals GmbH, Blaubeuren, Germany  
1996-99: R&D-Director, Member of the Board, Merckle Pharmaceuticals, Ulm, Germany  
1996-99: Managing Director, Asahi-Merckle-Pharma, Ulm, Germany  
1996-07: Member of the Board, ProGen Biotech GmbH, Heidelberg, Germany  
1999-present: Chairman for Pharmaceutical Chemistry, Head Medicinal Chemistry  
Eberhard-Karls-University Tuebingen, Germany  
2003-06: Dean Faculty Chemistry and Pharmacy  
2003-06: Director Institute of Pharmacy  
2003-present: Founding Dean Pharmacy German University in Cairo  
2005-present: Director Brasilienzentrum Baden-Württemberg  
2008-present: Cofounder ICEPHA, 2011-2018 Chairman of the board  
(Interfaculty Centre for Pharmacogenomics and Pharma Research)  
2006-15: Vice President Board of Trustees Eberhard-Karls-University Tuebingen  
2008-13: Member of the Board, BioPro Baden-Württemberg GmbH, Stuttgart, Germany  
2015: Tuebingen Center for Academic Drug Discovery & Development (TüCAD<sub>2</sub>)  
Cofounder and Chairman  
2019-2024: Director Institute of Pharmacy

### ***Postgraduate Education:***

- 1989: Board Certified Specialist Pharmaceutical Analytics (Fachapotheker)  
1994: Board Certified Specialist Toxicology (Fachapotheker)  
1997: Advanced Management Training, European Inst. Business Administration INSEAD, Fontainebleau, France

### ***Memberships:***

American Chemical Society, Medicinal Chemistry Division  
Gesellschaft Deutscher Chemiker GDCh  
Deutsche Pharmazeutische Gesellschaft DPhG  
Österreichische Pharmazeutische Gesellschaft ÖPhG  
DECHEMA, ChemBioNet  
Inflammation Research Association

### ***Scientific Board Positions:***

Deutsche Pharmazeutische Gesellschaft DPhG (German Pharmaceutical Society)  
President 2016-9, 2012-15 Vice President, since 2008 Vice President MedChem Division  
Wiley ArchPharm, 2016-19 Senior Editor, since 2020 Honorary Editor  
Gesellschaft Deutscher Chemiker (GDCh), since 2015 Board Member MedChem Division  
DECHEMA: 2012-17 Board Member ChemBioNet  
Journal of Medicinal Chemistry (ACS): 2010-20 Editorial Advisory Board Member, since 2021 Associate Editor  
Research Commission Medical Faculty Uni Tuebingen, AKF, Member since 2001  
Interfaculty Center for Pharmacogenomic and Drug Research (ICEPHA), Co-Founder and Chairman 2011-2020  
INCT-INOFAR of Drugs and Medicines, UFRJ, Brasil, Scientific Advisory Board since 2014  
Center for Personalized Medicine Uni Tuebingen, Board Member since 2015  
Chemical Probes Portal SGC-UNC, Member Scientific Advisory Board since 2015

### ***Research:***

Medicinal Chemistry/Drug Discovery, Molecular targets: COX-1/2/3, Lipoxygenases, cPLA<sub>2</sub>, mPGES1, Cytokine-Release Inhibitors, **Proteinkinase-Inhibitors**, Transcription factors, Replication Proteins, Translational Academic Drug Discovery, 5 cpds first into man.

### ***Honors (selected):***

- 1998: Chair Pharm. Chemistry (C4), Uni Bonn, rejected  
1999: Chair Pharm. Chemistry, Uni Tübingen (C4), accepted  
2003: Chair Pharm. Chemistry, Uni Freiburg, rejected  
2006 and 2017: Phoenix Wissenschaftspreis Pharmazie  
2014: Permanent Member (Membro Correspondente) of the Brazilian Academy of Science  
2016: Teaching Award Faculty of Medicine: Best Lecturer (Advanced Molecular Oncology)  
2017: ACS Journal Stars: Medicinal Chemistry, Top 10 (#5) most prolific author 2010-16  
2024: Mannich-Award of the German Pharmaceutical Society (DPhG)

## Postgraduate Teaching/Supervision

>100 Master-/Diploma Thesis

>100 PhD Thesis (Dr. rer. nat.)

4 Habilitations, Juniorprofessorships (Christian Peifer: now W3 in Kiel, Bernd Kammerer: now W3 in Freiburg, Pierre Koch: offer for W3 in Regensburg, Gehringer: JProf.)

12 PostDocs (Mathieu, Kaptur, Abu Rayyan, Schimpp, Mohr, Selig, Abu Rayan, Bäuerlein, Geier, Kronenberger, Pillaiyar, Galvez)

## Hosted Guest Professors

Lawrence Marnett (Vanderbilt)

Peter Bernstein (PhaRmaB LLC)

Antti Poso (UEF)

Bassam Abu Thaher (IUGAZA)

Marcia Goettert (UNIVATES)

Ryoichi Fujiwara (Kitasato University)

## Publications (full list below)

Google Scholar as of October 24, 2024

(<https://scholar.google.de/citations?user=9o3OjqsAAAAJ&hl=de>)

699 Publications

Citations	all	since 2019
	19047	8650
h-index	73	40
i10-index	309	205

Including Nature Communications, Nature Cancer, Nature Medicine (2), PNAS (2), Nature Chem. Biol., JACS, Lancet, Cell, Angew. Chemie (12), ACS J. Med. Chem. (67)

**ORCID:** <https://orcid.org/0000-0001-6952-1486>

## Patents (full list below, attachment 3)

DEPATISnet: 51 Patent Families, 393 National Applications

<https://depatisnet.dpma.de/DepatisNet/depatisnet?window=1&space=main&content=basis&action=treffer&firstdoc=1#errormsg>

## 17 Books/Book-Chapters (full list below; attachment 2)

### Talks and Lectures

>300, including Gordon Conference, ACS, EFMC, IUPAC

in 2021: EFMC, UEF, SBFTTE, UFRJ, Brasilia (CNPq/Capes/DWIH), ACS, BW-Stiftung, UIBK, LAK-BW, UNIVATES, ETH, PUCRS, ECBS

## **Grants (selected):**

### **Funding Agency European Union (EU)**

Macrocept (FP6)  
Kinacept (FP7)  
Pep2Brain,  
Marie-Curie Program CSI AurKa  
Submitted: NODE

### **Funding Agency DFG (German Research Foundation)**

FOR 2314 (Forschungsgruppen)

- HECT ligase inhibition for cancer therapy
- MYC Destabilisierung durch konformationsändernde Aurora-A Liganden als Therapiestrategie beim Hepatozellulären Karzinom
- Inhibition des Replikationsproteins Rpa3 als neues Therapiekonzept zur Behandlung solider Tumore

Excellence Initiative, Excellence Cluster iFIT (Individualisierung von Tumortherapien durch molekulare Bildgebung und funktionelle Identifizierung therapeutischer Zielstrukturen  
Projects: iFIT-PPI, iFIT-ATM, iFIT-LXR

Exzelle Strategy (ExStra), Tübingen Center for Academic Drug Discovery (TüCADD)

Kinase 2.0

Under Evaluation: NFDI4Chem – Fachkonsortium Chemie in der NFDI

### **Funding Agency BMBF (Federal Ministry of Higher Education)**

C-a-i-r Biosciences (Bioprofile Programm Stuttgart/Neckar-Alb)  
Neuroalliance  
Synthetische Sialinsäureliganden  
GUC (DAAD/Auswärtiges Amt)  
Ibuprofen-SCI-Safety

### **Funding Agency DAAD-BMBF (German Academic Exchange Service)**

DAAD-TNB, German University in Cairo

### **Funding Agency MWK (Ministry of Science, Research and the Arts, Baden-Württemberg)**

Inhaltsstoffe von Arzneipflanzen Südbrasilien  
Forum Gesundheitsstandort Baden-Württemberg

- DiHeSysy, 3D-Druck von Arzneimitteln
- BWCADD

MINT-Programm

## **Foundations**

Baden-Württemberg Stiftung

- Improve CRC
- Flavivirus-Blocker
- Antiviral Therapies

Robert Bosch Stiftung

- ICEPHA

Fonds der Chemischen Industrie VCI

Deutsche Krebshilfe

- Präklinische Wirkstoffentwicklung-Onkogene Transkription als Zielstruktur für neue Krebstherapie

## **Industry, Venture Capital**

CAIR Biosciences GmbH,

Heparegenix GmbH

Materia Medica

Crystal16